drugset / Trial / NCT01742793
An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study hypothesis is that lenalidomide and romidepsin (and dexamethasone for patients with myeloma) will have an acceptable toxicity profile and that in combination will have sufficient activity in the target population (including those previously refractory to HDACi monotherapy) to warrant further investigation.
Timeline
- Start
- 2012-10
- Primary completion
- 2016-08
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 15 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Subject | Romidepsin | Peptide | 6 mg | Intravenous |
| Subject | Romidepsin | Peptide | 8 mg | Intravenous |
| Subject | Romidepsin | Peptide | 10 mg | Intravenous |
| Subject | Romidepsin | Peptide | 12 mg | Intravenous |
| Subject | Romidepsin | Peptide | 14 mg | Intravenous |